IL315441A - Treatment methods for small cell lung cancer - Google Patents

Treatment methods for small cell lung cancer

Info

Publication number
IL315441A
IL315441A IL315441A IL31544124A IL315441A IL 315441 A IL315441 A IL 315441A IL 315441 A IL315441 A IL 315441A IL 31544124 A IL31544124 A IL 31544124A IL 315441 A IL315441 A IL 315441A
Authority
IL
Israel
Prior art keywords
methods
lung cancer
small cell
cell lung
treating small
Prior art date
Application number
IL315441A
Other languages
English (en)
Hebrew (he)
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of IL315441A publication Critical patent/IL315441A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL315441A 2022-03-07 2023-03-07 Treatment methods for small cell lung cancer IL315441A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22160556 2022-03-07
PCT/EP2023/055751 WO2023170065A1 (en) 2022-03-07 2023-03-07 Methods of treating small cell lung cancer

Publications (1)

Publication Number Publication Date
IL315441A true IL315441A (en) 2024-11-01

Family

ID=80682926

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315441A IL315441A (en) 2022-03-07 2023-03-07 Treatment methods for small cell lung cancer

Country Status (12)

Country Link
US (1) US20260027117A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489756A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509278A (cg-RX-API-DMAC7.html)
KR (1) KR20240158972A (cg-RX-API-DMAC7.html)
CN (1) CN118843466A (cg-RX-API-DMAC7.html)
AR (1) AR128711A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023232376A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253688A1 (cg-RX-API-DMAC7.html)
IL (1) IL315441A (cg-RX-API-DMAC7.html)
MX (1) MX2024010900A (cg-RX-API-DMAC7.html)
TW (1) TW202337469A (cg-RX-API-DMAC7.html)
WO (1) WO2023170065A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) * 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
CN118581045A (zh) * 2024-07-29 2024-09-03 云南省肿瘤医院(昆明医科大学第三附属医院) 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
EP2817308B1 (en) 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
CA3043945A1 (en) 2016-11-16 2018-05-24 Sui Xiong Cai 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6h)-ones
GB201703881D0 (en) * 2017-03-10 2017-04-26 Almac Discovery Ltd Pharmaceutical compounds
WO2022155202A1 (en) 2021-01-13 2022-07-21 Schrödinger, Inc. Fused heterocycles and uses of same
WO2022188802A1 (en) * 2021-03-10 2022-09-15 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer
US20240254123A1 (en) 2021-06-04 2024-08-01 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
WO2023093840A1 (en) * 2021-11-26 2023-06-01 Impact Therapeutics (Shanghai) , Inc Use of wee1 kinase inhibitors in the treatment of cancer

Also Published As

Publication number Publication date
EP4489756A1 (en) 2025-01-15
JP2025509278A (ja) 2025-04-11
WO2023170065A1 (en) 2023-09-14
KR20240158972A (ko) 2024-11-05
TW202337469A (zh) 2023-10-01
CN118843466A (zh) 2024-10-25
US20260027117A1 (en) 2026-01-29
AR128711A1 (es) 2024-06-05
MX2024010900A (es) 2024-09-17
AU2023232376A1 (en) 2024-10-10
CA3253688A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
EP4153176A4 (en) METHODS OF TREATING CANCER
EP4232039A4 (en) METHODS OF TREATING LUNG CANCER
EP4111202A4 (en) CANCER TREATMENT METHODS
IL320962A (en) Methods for treating advanced solid tumors
IL320743A (en) A method for treating prostate cancer
IL326946A (en) Methods of treating non-small cell lung cancer
EP4281063A4 (en) OXABICYCLOHEPTANE FOR THE TREATMENT OF SMALL CELL LUNG CANCER
IL326327A (en) Treatment of prostate cancer
HK40119480A (en) Methods of treating small cell lung cancer
IL326029A (en) Treating non-small cell lung cancer with alectinib
IL314687A (en) Cancer treatment
IL312155A (en) A method for treating cancer
CA3303567A1 (en) Methods of treating non-small cell lung cancer
IL272390A (en) Cancer treatment methods
IL315569A (en) Cancer treatment methods
IL320448A (en) Methods of treating cancer using sutorsiv
CA3288585A1 (en) Treatment of non-small cell lung cancer
AU2022903198A0 (en) Methods for treating small cell lung cancer
AU2024377510A1 (en) Methods of treating cancer
CA3310617A1 (en) Methods of treating cancer
CA3293232A1 (en) Methods of treating cancer
IL312332A (en) Cancer treatment methods
GB202308906D0 (en) Treatment of trbc1-positive T cell malignancies
IL314798A (en) Prostate cancer treatment methods
CA3270268A1 (en) Methods of treating cancer with sotorasib